Anaphylactic shock after retreatment with basiliximab.
Barros
V R
VR
Complexo Hospitalar Santa Casa-FFFCMPA, Porto Alegre, Brazil.
Rocha
V
V
Garcia
V D
VD
Garcia
C D
CD
D000707:Anaphylaxis / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D000077552:Basiliximab; D002675:Child, Preschool; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D016030:Kidney Transplantation; D011993:Recombinant Fusion Proteins; D019233:Retreatment
D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab